Mateusz Kowalik, Joanna Masternak and Barbara Barszcz* Pages 729 - 759 ( 31 )
Background: Application of coordination chemistry in nanotechnology is a rapidly developing research field in medicine. Bismuth complexes have been widely used in biomedicine with satisfactory therapeutic effects, mostly in Helicobacter pylori eradication, but also as potential antimicrobial and anti-leishmanial agents. Additionally, in recent years, application of bismuth-based compounds as potent anticancer drugs has been studied extensively.
Methods: Search for data connected with recent trends on bismuth compounds in cancer chemo- and radiotherapy was carried out using web-based literature searching tools such as ScienceDirect, Springer, Royal Society of Chemistry, American Chemical Society and Wiley. Pertinent literature is covered up to 2016.
Results: In this review, based on 213 papers, we highlighted a number of current problems connected with: (i) characterization of bismuth complexes with selected thiosemicarbazone, hydrazone, and dithiocarbamate classes of ligands as potential chemotherapeutics. Literature results derived from 50 papers show that almost all bismuth compounds inhibit growth and proliferation of breast, colon, ovarian, lung, and other tumours; (ii) pioneering research on application of bismuth-based nanoparticles and nanodots for radiosensitization. Results show great promise for improvement in therapeutic efficacy of ionizing radiation in advanced radiotherapy (described in 36 papers); and (iii) research challenges in using bismuth radionuclides in targeted radioimmunotherapy, connected with choice of adequate radionuclide, targeting vector, proper bifunctional ligand and problems with 213Bi recoil daughters toxicity (derived from 92 papers).
Conclusion: This review presents recent research trends on bismuth compounds in cancer chemo- and radiotherapy, suggesting directions for future research.
Bismuth(III) complexes, anticancer properties, chemotherapeutics, Bi-based nanoparticles, radiation therapy, 213Bi alpha-targeted radioimmunotherapy.
Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce